DOCSLIB.ORG

Common Derm Conditions and Treatments

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

4/10/17 Classes of Dermatologic Medications What is that?! Common Dermatologic Conditions and ● Topical Immune Suppressants ● Immune Suppressants How to Treat Them ● Vitamin D Derivatives ● Antibiotics, Antivirals, Antiparasitic Matthew Fox, MD ● Retinoids ● Antimalarials Assistant Professor, Division of Dermatology ● Biologic Agents Dell Medical School, University of Texas at Austin Director of Dermatologic Surgery, Seton Healthcare Family ● Chemotherapeutic agents Learning Objectives Approach to Dermatologic Conditions • Know the clinical subtypes of acne *Know the mechanism and recommended dosing of topical retinoids, oral antibiotics and oral retinoids in the management of acne Acne • Understand the clinical presentation cutaneous dermatophyte infection Infectious diseases of the Skin *Know the classes and recommended dosing of antifungal treatments • Recognize the clinical manifestations of dermatitis Eczema *Know the relative potencies, side effects and indications of topical steroids Psoriasis • Describe the classic clinical findings for psoriasis *Know the mechanism of action and side effects of systemic antipsoriatic medications Sun Damage / Actinic Keratoses • Know the pertinent history and physical exam findings associated with a diagnosis of skin cancer, including the ABCDEs of melanoma Fundamentals Words to the wise… • All medications have side effects If you advise the patients of side effects ahead of time, you are informing the • Always consider drug interactions, patient. including with food and supplements If you did not tell the patient about a known • Always consider pregnancy and lactation side effect until after they experience status that side effect, it is an excuse 1 4/10/17 Reference: Approach to Dermatologic Conditions • Wolverton SE, ed. Acne Comprehensive Infectious diseases of the Skin Dermatologic Drug Eczema nd Therapy, 2 Ed. Psoriasis Elsevier, 2007. Sun Damage / Actinic Keratoses Topical Retinoids Retinoid RAR-α RAR-β RAR-γ RXR-α RXR-β RXR-γ • Small molecule hormones that activate All-trans retinol - - - - - - nuclear receptors and regulate gene All-trans retinoic acid ++ ++ ++ - - - Adapalene Weak ++ ++ - - - transcription Tazarotenic acid + +++ ++ - - - Alitretinoin +++ +++ +++ ++ ++ ++ Bexarotene - - - +++ +++ +++ Retinoids: Clinical Effects Adapalene • Affect pathways involved in: • Mild comedonal acne – Inflammation – Cellular differentiation • 0.1% gel – Apoptosis • Apply QHS – Sebaceous gland differentiation • OTC (2016) ***NORMALIZATION OF FOLLICULAR EPITHELIAL • Pregnancy: C DIFFERENTIATION AND KERATINIZATION*** 2 4/10/17 Tretinoin Tazarotene • Supplied as 0.025%, 0.05%, 0.1% cream • 0.05% and 0.1% cream and gel or as 0.01 - 0.1% gel • Apply QHS • Apply QHS • For female patients, begin during menses • May need to start with lesser frequency • Pregnancy: X • Pregnancy: C Topical Antibiotics Clindamycin Name Comments • Reversibly binds 50s subunit of ribosomal Benzoyl Beneficial effects can be neutralized with simultaneous tretinoin peroxide No association with induction of bacterial resistance RNA subunit à inhibition of protein synthesis Clindamycin Good gram + and anaerobic coverage • Broad spectrum(S. aureus, streptococci, P. Erythromycin Resistance to some P. acnes; most benefit is via anti-inflammatory effec ts acnes) Metronidazole Coverage of both aerobic and anaerobic bacteria (more for rosacea) • 1% lotion or solution, applied daily to BID Azelaic ac id Broad coverage; good for pigmentary disorders; OK during pregnancy • Pustules, inflammatory acne >> non- Sodium Broad coverage and multiple indications inflammatory lesions sulfac etamide Azelaic acid Sodium sulfacetamide • Commonly incorporated in formulation with • Activity against tyrosinase sulfur • Safe during pregnancy (B) • Inhibition pro-inflammatory enzymes • Supplied as 15% gel • Supplied as lotion for BID application 3 4/10/17 Benzoyl peroxide Combination products • Keratolytic and comedolytic properties • Improved patient adherence • Bactericidial, broad spectrum • Better results that individual agents alone • Broad range of concentrations (2.5-10%) • Many combinations: and vehicles (washes, lotion, gel, cream) – BPO/Clindamycin combinations • Little to no induction of bacterial resistance – Clindamycin/retinoid combinations • Peeling, erythema, dryness Oral antibiotics Tetracyclines • Tetracyclines • Bacteriostatic, inhibit bacterial protein synthesis • Trimethoprim/sulfonamide • Bind 30S ribosomal subunit • Clindamycin • Do not give to children < 9 – bone, teeth development • Pregnancy category D Minocycline Doxycycline • Supplied: 50, 75, 100 mg • Supplied: 20, 50, 75, 100 mg • Dosage: 50-200 mg per day (dosed daily or BID) • Dosage: 50-200 mg per day (dosed daily or BID) • Common SEs: • Common SEs: – Dizziness – GI (burning, discomfort, nausea, vomiting) – Headache (pseudotumor cerebri) • Relieved if taken with food (NON DAIRY) – GI – Photosensitivity – Photosensitivity – Headache – Pigmentation change – Pigmentary change – Hepatotoxic – Hepatotoxic • Not to be used in pregnancy, kids • Not to be used in pregnancy, kids • Not to be used with isotretinoin: increased risk of • Not to be used with isotretinoin: increased risk of pseudotumor cerebri (applies to all tetracyclines) pseudotumor cerebri (applies to all tetracyclines) 4 4/10/17 Oral retinoids - Isotretinoin Isotretinoin • Approved for severe recalcitrant nodular • Dosage: acne – Weight based dosing – Inflammatory lesions greater than 5mm in – 0.5-1 mg/kg daily, until a total cumulative dose diameter of 120-150 mg/kg is reached – Unresponsive to conventional tx (oral abx) • Rate of success approx 70% • Consider impact of disease on patient! – Relapses more likely to respond to conventional treatment ADVERSE EFFECTS Alternative acne treatment Teratogenicity Hepatic -Retinoic acid embryopathy -Elevated transaminases Ocular Other Endocrine • For ‘hormonal’ acne, may consider -Reduced night vision -Hypothyroidism -Dry eyes, infection – Spironolactone Bone Hematologic -Diffuse skeletal hyperostosis -Leukopenia • SE: Teratogenic, K+ monitoring -Premature epiphyseal closure -Agranuloc ytosis – OCPs Lipids Neuro/Psych -Elevated cholesterol, TG -Depression, pseudotumor Gastrointestinal Muscle -Inflammatory bowel disease flare -Myalgias -Pancreatitis Acne Pearls Approach to Dermatologic Conditions • For acne on the trunk, it is difficult for patients to apply lotions, gels. Use washes and oral Acne antibiotics. • For medications to work, it takes time. Advise Infectious diseases of the Skin that the earliest they will see improvement is Eczema 6-8 weeks. Psoriasis • Often need combination of products • May need oral retinoids sooner than later! Sun Damage / Actinic Keratoses 5 4/10/17 Warts Impetigo Treatment Comments Salicylic Ac id Keratolytic; consider 40% plaster under occlusion • Mupirocin Podophyllin Antimitotic agent; contraindicated in pregnanc y; applied in offic e • Staph directed antibiotic coverage Cantharidin Vesic ulating agent; applied in office – Bactrim Imiquimod Immunostimulatory (activates TLR-7); apply at bedtime three times – Clindamycin weekly on non-consecutive days (genital warts) – Doxycycline Candida Immunostimulatory, injec ted into lesion Antigen – Cephalosporins Mupirocin Acyclovir / valacyclovir • Inhibits bacterial isoleucyl-tRNA synthetase à inhibits bacterial RNA and cell wall • Guanosine analog synthesis • Requires phosphorylation by herpes • Excellent coverage against S. aureus, S. epidermidis, S.pyogenes, B-hemolytic specific thymidine kinase Streptococci • Once active, inhibits viral DNA polymerase • ? Resistance • Valacyclovir is oral prodrug • 2% ointment, to be applied BID • Exceptionally safe and well tolerated • SE: burning, itching, contact dermatitis Herpes viruses Scabies Treatments • Topical acyclovir • Permethrin: – Supplied as 5% ointment for limited disease – low efficacy – MOA: acts on arthropod cell wall by disabling sodium – applied Q3 hours, 6x/day for 7 days transport à mite paralysis • Acyclovir – Supplied as oral suspension – Applied from neck to, not just visibly affected sites – Example doses: – Two overnight applications separated by one week • Cold sore: 400 mg 5x/day for 5 days • Shingles: 800 mg 5x/day for 7-10 days – All partners and close contacts should be treated • Valacyclovir – Reasonable to wash clothes and linens concurrent – Easier dosing, possible benefit for PHN • Cold sore: 2g twice daily for one day with treatment • Shingles: 1g TID x 7 days – Pruritus may last for up to 1 month after treatment! 6 4/10/17 Scabies Treatments Azole antifungals • Sulfur: MOA: Inhibition of 14α-demethylase, leading to decreased ergosterol formation – time honored Examples include: – 6% precipitated sulfured, compounded, applied daily until improved • Ketoconazole – 2% cream, applied BID until improved • Ivermectin: – 1-2% shampoo, used in seborrheic dermatitis – MOA: blocks glutamate gated chloride ion channels à paralysis of arthropod/helminth • Econazole – 1% cream, applied BID until improved – Off label: single 100-200 μg/kg dose or two full doses separated by one week • Efinaconazole – 10% topical solution, painted topically to nails once daily for 48 weeks! Te rb i n a fi n e Oral terbinafine • Allylamine, disrupts fungal cell wall via • Severe or resistant fungal infection • 250 mg daily for: inhibition of squalene epoxidase – 2 weeks (tinea corporis) – 6 weeks (fingernails) • Highly lipophilic (high concentration in – 12 weeks (toenails) stratum corneum, hair follicles, sebum) • Common SEs: HA, GI
Recommended publications
  • Therapeutic Class Overview Antifungals, Topical

    Therapeutic Class Overview Antifungals, Topical

    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
  • Federal Register/Vol. 83, No. 31/Wednesday, February 14, 2018

    Federal Register/Vol. 83, No. 31/Wednesday, February 14, 2018

    Federal Register / Vol. 83, No. 31 / Wednesday, February 14, 2018 / Notices 6563 Wireless Telecommunications Bureau Signed: DEPARTMENT OF HEALTH AND and Wireline Competition Bureau (the Dayna C. Brown, HUMAN SERVICES Bureaus) may implement, and (3) certify Secretary and Clerk of the Commission. Centers for Disease Control and its challenge. The USAC system will [FR Doc. 2018–03166 Filed 2–12–18; 4:15 pm] validate a challenger’s evidence using Prevention BILLING CODE 6715–01–P an automated challenge validation [CDC–2018–0004; NIOSH–233–B] process. Once all valid challenges have been identified, a challenged party that NIOSH List of Antineoplastic and Other chooses to respond to any valid FEDERAL RESERVE SYSTEM Hazardous Drugs in Healthcare challenge(s) may submit additional data Settings: Proposed Additions to the via the online USAC portal during the Change in Bank Control Notices; NIOSH Hazardous Drug List 2018 established response window. A Acquisitions of Shares of a Bank or AGENCY: Centers for Disease Control and challenged party may submit technical Bank Holding Company information that is probative regarding Prevention, HHS. ACTION: Notice of draft document the validity of a challenger’s speed tests, The notificants listed below have available for public comment. including speed test data and other applied under the Change in Bank device-specific data collected from Control Act (12 U.S.C. 1817(j)) and transmitter monitoring software or, SUMMARY: The National Institute for § 225.41 of the Board’s Regulation Y (12 alternatively, may submit its own speed Occupational Safety and Health test data that conforms to the same CFR 225.41) to acquire shares of a bank (NIOSH) of the Centers for Disease standards and requirements specified by or bank holding company.
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
  • Nails: Tales, Fails and What Prevails in Treating Onychomycosis

    Nails: Tales, Fails and What Prevails in Treating Onychomycosis

    J. Hibler, D.O. OhioHealth - O’Bleness Memorial Hospital, Athens, Ohio AOCD Annual Conference Orlando, Florida 10.18.15 A) Onychodystrophy B) Onychogryphosis C)“Question Onychomycosis dogma” – Michael Conroy, MD D) All the above E) None of the above Nail development begins at 8-10 weeks EGA Complete by 5th month Keratinization ~11 weeks No granular layer Nail plate growth: Fingernails 3 mm/month, toenails 1 mm/month Faster in summer or winter? Summer! Index finger or 5th digit nail grows faster? Index finger! Faster growth to middle or lateral edge of each nail? Lateral! Elkonyxis Mee’s lines Aka leukonychia striata Arsenic poisoning Trauma Medications Illness Psoriasis flare Muerhrcke’s bands Hypoalbuminemia Chemotherapy Half & half nails Aka Lindsay’s nails Chronic renal disease Terry’s nails Liver failure, Cirrhosis Malnutrition Diabetes Cardiovascular disease True or False: Onychomycosis = Tinea Unguium? FALSE. Onychomycosis: A fungal disease of the nails (all causes) Dermatophytes, yeasts, molds Tinea unguium: A fungal disease of nail caused by dermatophyte fungi Onychodystrophy ≠ onychomycosis Accounts for up to 50% of all nail disorders Prevalence; 14-28% of > 60 year-olds Variety of subtypes; know them! Sequelae What is the most common cause of onychomycosis? A) Epidermophyton floccosum B) Microsporum spp C) Trichophyton mentagrophytes D) Trichophyton rubrum -Account for ~90% of infections Dermatophytes Trichophyton rubrum Trichophyton mentagrophytes Trichophyton tonsurans, Microsporum canis, Epidermophyton floccosum Nondermatophyte molds Acremonium spp, Fusarium spp Scopulariopsis spp, Sytalidium spp, Aspergillus spp Yeast Candida parapsilosis Candida albicans Candida spp Distal/lateral subungal Proximal subungual onychomycosis onychomycosis (DLSO) (PSO) Most common; T. rubrum Often in immunosuppressed patients T.
  • R Topical Antifungals

    R Topical Antifungals

    Send completed form to: Service Benefit Plan Prior Approval TOPICAL ANTIFUNGALS P.O. Box 52080 MC 139 PRIOR APPROVAL REQUEST Phoenix, AZ 85072-2080 Attn. Clinical Services Additional information is required to process your claim for prescription drugs. Please complete the cardholder portion, and have the prescribing physician complete the physician portion and submit this completed form. Fax: 1-877-378-4727 Patient Information (required) Provider Information (required) Date: Provider Name: Patient Name: Specialty: NPI: Date of Birth: Sex: Male Female Office Phone: Office Fax: Street Address: Office Street Address: City: State: Zip: City: State: Zip: Patient ID: Physician Signature: R PHYSICIAN COMPLETES Topical Antifungals NOTE: Form must be completed in its entirety for processing Please select medication and bottle size: ❑ Jublia 4 mL (efinaconazole) ❑ Kerydin 4 mL (tavaborole) ❑ Jublia 8 mL (efinaconazole) ❑ Kerydin 10 mL (tavaborole) **Check www.fepblue.org/formulary to confirm which medication is part of the patient’s benefit Is this request for brand or generic? ❑ Brand ❑ Generic How many bottles will the patient need for an 84-day supply? __________ bottle(s) per 84 days 1. What is the patient’s diagnosis? ❑ Onychomycosis a. Where is the fungal infection located? ❑Fingernail(s) ❑Toenail(s) ❑ Other location (please specify): _______________________________________ ❑ Other fungal infection (please specify): _____________________________________________________________________ ❑ Other diagnosis (please specify): __________________________________________________________________________
  • New Pharmacotherapy for the Treatment of Onychomycosis: an Update

    New Pharmacotherapy for the Treatment of Onychomycosis: an Update

    Review New pharmacotherapy for the treatment of onychomycosis: an update 1. Introduction † Aditya K Gupta & Fiona C Simpson 2. Orals † Mediprobe Research, Inc., London, ON, Canada 3. Topicals 4. Laser therapy Introduction: Onychomycosis is an infection of the nail plate that is an impor- 5. Conclusion tant priority area for the development of antifungal drugs. The high incidence of relapse and reinfection often makes onychomycosis a chronic condition. 6. Expert opinion The current gold standard is oral therapy, but the development of effective topical agents remains a priority as they have fewer systemic interactions. Areas covered: This review summarizes development of antifungals from early phase development through Phase III clinical trials for onychomycosis. The oral molecules in development are azole molecules. Topical drugs in development include azoles, allylamines, benzoxaboroles and nanoemul- sions. Photosensitizers for photodynamic therapy and new laser systems are also emerging therapeutic options. There is a diverse array of antifungal drugs in the early phases of development. Expert opinion: The goals of onychomycosis therapy are a mycological cure and a normal appearing nail. The recent development of topical antifungals has been successful at improving the nail permeation and efficacy. The diversifica- tion of molecular targets is the next primary goal of antifungal development. Incomplete treatment of onychomycosis provides an environment conducive to the development of antifungal resistance. New topical agents and device- based therapies expand the therapeutic options. Combination therapy using For personal use only. multiple drug classes may improve the overall efficacy of antifungal treatment in onychomycosis. Keywords: allylamine, antifungal, azole, dermatophyte, non-dermatophyte mold, onychomycosis Expert Opin.
  • New Drugs for Treating Fungal Infections a Review of Recent Developments for Efficacious Treatment

    New Drugs for Treating Fungal Infections a Review of Recent Developments for Efficacious Treatment

    COVER FOCUS New Drugs for Treating Fungal Infections A review of recent developments for efficacious treatment. BY NEAL BHATIA, MD, FAAD, AND TED ROSEN, MD here have been many recent additions to the arma- mentarium—from new dosing protocols to new PRACTICAL POINTER drugs—for treating onychomycosis and other fungal infections. And there are other potential new thera- Tavaborole represents a new class of antifungals. piesT on the way. Here, we’ll review the latest research. Tavaborole inhibits an essential fungal enzyme, leucyl transfer RNA synthetase, or LeuRS, required for protein Luliconazole Cream 1%. In 2013, the FDA approved Luzu synthesis, which leads to termination of cell growth and (luliconazole, Valeant) Cream, 1% for the topical treatment of cell death, eliminating the fungal infection. interdigital tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and older. It is the first topical azole antifungal Naftifine Gel 2%. Last year, the FDA approved Naftin (naf- agent approved to treat tinea cruris and tinea corporis with a tifine HCl, Merz North America) Gel 2% for the treatment of one-week, once-daily treatment regimen. All other approved interdigital-type tinea pedis. Naftin Gel 2% improves on the treatments require two weeks of treatment. Interdigital tinea current formulation of Naftin Gel 1% by delivering the efficacy pedis is approved with a two-week, once-daily treatment. of naftifine hydochloride with a once-daily application treat- In a Phase II study of luliconazole for the treatment of inter- ment regimen. In clinical studies, Naftin Gel 2% demonstrated digital tinea pedis, complete clearance was achieved in 26.8 continuous improvement in post-treatment efficacy rates for percent and 45.7 percent of subjects in the two-week and up to four weeks after treatment regimen had ended.
  • FDA Briefing Document Pharmacy Compounding Advisory Committee

    FDA Briefing Document Pharmacy Compounding Advisory Committee

    FDA Briefing Document Pharmacy Compounding Advisory Committee (PCAC) Meeting June 23, 2016 The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the Pharmacy Compounding Advisory Committee (advisory committee). We are bringing certain compounding issues to this advisory committee to obtain the committee’s advice. The background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. The FDA does not intend to issue a final determination on the issues at hand until input from the advisory committee process has been considered, all reviews have been finalized, consultation with the United States Pharmacopeia has occurred, and public comment has been considered through notice and comment rulemaking. The final determination may be affected by issues not discussed at the advisory committee meeting. Table of Contents I. Introduction ................................................................................................................... 3 A. Bulk Drug Substances That Can Be Used by Compounders under
  • The Dermatologist's Approach to Onychomycosis

    The Dermatologist's Approach to Onychomycosis

    J. Fungi 2015, 1, 173-184; doi:10.3390/jof1020173 OPEN ACCESS Journal of Fungi ISSN 2309-608X www.mdpi.com/journal/jof Review The Dermatologist’s Approach to Onychomycosis Jenna N. Queller 1 and Neal Bhatia 2,* 1 Dermatology Chief Resident at Harbor-UCLA Medical Center, Torrance, CA 90502, USA; E-Mail: [email protected] 2 Director of Clinical Dermatology, Therapeutics Clinical Research, San Diego, CA 92123, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-858-571-6800. Academic Editor: Theodore Rosen Received: 24 June 2015 / Accepted: 5 August 2015 / Published: 19 August 2015 Abstract: Onychomycosis is a fungal infection of the toenails or fingernails that can involve any component of the nail unit, including the matrix, bed, and plate. It is a common disorder that may be a reservoir for infection resulting in significant medical problems. Moreover, onychomycosis can have a substantial influence on one’s quality of life. An understanding of the disorder and updated management is important for all health care professionals. Aside from reducing quality of life, sequelae of the disease may include pain and disfigurement, possibly leading to more serious physical and occupational limitations. Dermatologists, Podiatrists, and other clinicians who treat onychomycosis are now entering a new era when considering treatment options—topical modalities are proving more effective than those of the past. The once sought after concept of viable, effective, well-tolerated, and still easy-to-use monotherapy alternatives to oral therapy treatments for onychomycosis is now within reach given recent study data. In addition, these therapies may also find a role in combination and maintenance therapy; in order to treat the entire disease the practitioner needs to optimize these topical agents as sustained therapy after initial clearance to reduce recurrence or re-infection given the nature of the disease.
  • Revised 1/23/2020 GEORGIA MEDICAID FEE-FOR-SERVICE ANTIFUNGALS, TOPICAL PA SUMMARY Preferred Non-Preferred LENGTH of AUTHORIZATI

    Revised 1/23/2020 GEORGIA MEDICAID FEE-FOR-SERVICE ANTIFUNGALS, TOPICAL PA SUMMARY Preferred Non-Preferred LENGTH of AUTHORIZATI

    GEORGIA MEDICAID FEE-FOR-SERVICE ANTIFUNGALS, TOPICAL PA SUMMARY Preferred Non-Preferred Ciclopirox 8% nail lacquer (solution)* Bensal HP (salicylic acid ointment) Ciclopirox cream, suspension generic Ciclodan Kit (ciclopirox 8% solution) Clotrimazole cream, solution Rx generic Ciclodan Cream Kit (ciclopirox cream 0.77%, Clotrimazole/betamethasone cream generic cleanser) Econazole cream generic CNL8 Nail Kit (ciclopirox 8% solution: 6-month Ketoconazole cream, shampoo generic supply and includes three 5mL bottles, 25 SwabPlus Miconazole generic nail lacquer remover swabs and 1 emery board) Nystatin cream, ointment, powder generic Ciclopirox gel, shampoo generic Nystatin/triamcinolone ointment generic Clotrimazole/betamethasone lotion generic Ertaczo (sertaconazole) Exelderm (sulconazole) Extina foam (ketoconazole 2%) Jublia (efinaconazole) Kerydin (tavaborole) Ketoconazole 2% foam Loprox Kit (ciclopirox suspension, cleanser) Luzu (luliconazole) Mentax (butenafine) Naftifine cream generic Nystatin/triamcinolone cream generic Oxistat (oxiconazole) Vusion (miconazole/petrolatum/zinc oxide) *preferred but requires PA LENGTH OF AUTHORIZATION: Varies NOTES: ▪ Ciclopirox nail lacquer is preferred but requires prior authorization (PA). ▪ Ertaczo, Exelderm, Mentax and Oxistat are non-preferred but do not require PA. PA CRITERIA: Bensal HP ❖ Approvable for members with a diagnosis of dermatitis who have experienced ineffectiveness, allergies, contraindications, drug-drug interactions or intolerable side effects with 3 topical corticosteroids. Ciclopirox
  • Fungal Infections from Human and Animal Contact

    Fungal Infections from Human and Animal Contact

    Journal of Patient-Centered Research and Reviews Volume 4 Issue 2 Article 4 4-25-2017 Fungal Infections From Human and Animal Contact Dennis J. Baumgardner Follow this and additional works at: https://aurora.org/jpcrr Part of the Bacterial Infections and Mycoses Commons, Infectious Disease Commons, and the Skin and Connective Tissue Diseases Commons Recommended Citation Baumgardner DJ. Fungal infections from human and animal contact. J Patient Cent Res Rev. 2017;4:78-89. doi: 10.17294/2330-0698.1418 Journal of Patient-Centered Research and Reviews (JPCRR) is a peer-reviewed scientific journal whose mission is to communicate clinical and bench research findings, with the goal of improving the quality of human health, the care of the individual patient, and the care of populations. REVIEW Fungal Infections From Human and Animal Contact Dennis J. Baumgardner, MD Aurora University of Wisconsin Medical Group, Aurora Health Care, Milwaukee, WI; Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI; Center for Urban Population Health, Milwaukee, WI Abstract Fungal infections in humans resulting from human or animal contact are relatively uncommon, but they include a significant proportion of dermatophyte infections. Some of the most commonly encountered diseases of the integument are dermatomycoses. Human or animal contact may be the source of all types of tinea infections, occasional candidal infections, and some other types of superficial or deep fungal infections. This narrative review focuses on the epidemiology, clinical features, diagnosis and treatment of anthropophilic dermatophyte infections primarily found in North America. Other human- acquired and zoonotic fungal infections also are discussed in brief.
  • Sharp Health Plan 2020 Formulary List of Covered Prescription Drugs

    Sharp Health Plan 2020 Formulary List of Covered Prescription Drugs

    2020 Formulary List of covered prescription drugs This drug list applies to all Large Group HMO and Large Group POS products, and the following Small Group HMO products: HMO GF 1, HMO GF 2, HMO GF 3, HMO GF 4, HMO GF 5, HMO GF 6, HMO GF 7, Bronze HDHP NG 1, CalChoice Bronze HDHP NG 3, CalChoice Bronze HMO NG 2, CalChoice Silver HMO NG 1, CalChoice Silver HMO NG 2, CalChoice Silver HMO NG 3, Silver HMO NG 1, Silver HMO NG 2, CalChoice Gold HMO NG 2, CalChoice Gold HMO NG 3, CalChoice Gold HMO NG 5, Gold HMO NG 1, Gold HMO NG 2, Gold HMO NG 3, Gold HMO NG 4, Gold HMO NG 5, Gold HMO NG 6, Gold HMO NG 7, CalChoice Platinum HMO NG 1, CalChoice Platinum HMO NG 2, CalChoice Platinum HMO NG 3, Platinum HMO NG 1, Platinum HMO NG 2, Platinum HMO NG 3, Platinum HMO NG 4, Platinum HMO NG 7, Platinum HMO NG 8 List of covered prescription drugs for Employer-sponsored plans from Sharp Health Plan An electronic version of this Prescription Drug List is available on the Sharp Health Plan website, by visiting sharphealthplan.com/search-drug-list You can find specific cost sharing information in your plan’s coverage documents by logging in to your Sharp Connect account on our website by visiting sharphealthplan.com/login This document is subject to change and all previous versions are no longer in effect. Last updated 12/01/2020. Table of Contents Introduction i-xii Definitions i How often does the Formulary change? iii Will I be notified of a Formulary change? iii How do I locate a Prescription Drug on the Formulary? iv How do I know if the drug listed